Olema Pharmaceuticals (OLMA): Price and Financial Metrics
OLMA Price/Volume Stats
| Current price | $8.28 | 52-week high | $16.77 |
| Prev. close | $8.72 | 52-week low | $8.12 |
| Day low | $8.12 | Volume | 357,500 |
| Day high | $8.79 | Avg. volume | 733,454 |
| 50-day MA | $11.77 | Dividend yield | N/A |
| 200-day MA | $12.02 | Market Cap | 474.43M |
OLMA Stock Price Chart Interactive Chart >
Olema Pharmaceuticals (OLMA) Company Bio
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
OLMA Price Returns
| 1-mo | -33.55% |
| 3-mo | -30.71% |
| 6-mo | -8.61% |
| 1-year | -39.78% |
| 3-year | -61.04% |
| 5-year | N/A |
| YTD | -40.98% |
| 2023 | 472.65% |
| 2022 | -73.82% |
| 2021 | -80.53% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...